Research programme: basal insulin analogues - AstraZeneca
Alternative Names: Insulin-Fc variantsLatest Information Update: 28 May 2022
At a glance
- Originator MedImmune
- Developer AstraZeneca
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in United Kingdom (SC, Injection)
- 03 Oct 2018 Pharmacodynamics data from a preclinical trial in type-2 diabetes mellitus presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD-2018)
- 01 Apr 2018 Preclinical trials in Type-2 diabetes mellitus in United Kingdom (SC)